MedTrace Logo

IBD Cancer and Serious Infection in Europe

NCT02377258 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13262

Last updated 2022-08-03

No results posted yet for this study

Summary

The primary objective of I-CARE is to assess prospectively the presence and the extent of safety concerns (cancers, especially, lymphoma, and serious infections risks) for anti-TNF alone or in combination with thiopurines among IBD patients.

We will stratify the risk of cancers and serious infections according to IBD phenotype and disease activity (clinical, radiologic and endoscopic).

Conditions

Interventions

OTHER

Non Interventional

Sponsors & Collaborators

  • Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

    lead OTHER

Principal Investigators

  • Laurent Peyrin-Biroulet, MD, PhD · Head of IBD Unit Inserm U954 Nancy University Hospital FRANCE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-04
Primary Completion
2022-05-16
Completion
2022-05-16

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02377258 on ClinicalTrials.gov